Clinical trial
Capecitabine in Treating Patients With Metastatic Prostate Cancer That Has Not…
NCT00006023 · Swiss Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00006023 |
|---|---|
| Title | Capecitabine in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy |
| Official title | Master Protocol for Metastatic Hormone-Resistant Prostatic Carcinoma - Phase II Trials - Protocol 5: Capecitabine |
| Lead sponsor | Swiss Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | capecitabine |
| Start date | Mar 1, 2000 |
| Primary completion | Jun 1, 2001 |
| Completion | Jun 1, 2001 |
| First posted | Mar 24, 2004 |
| Last update posted | Jun 26, 2019 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: